Human induced pluripotent stemcells, Credit: Wyss Institue

ReadCoor Receives Grant from
Chan Zuckerberg Initiative

Research to map spatial distributions
of cell types for the Human Cell Atlas

Learn more keyboard_arrow_up

ReadCoor, Inc., a company reinventing omics and pathology with its panomic spatial sequencing platform, today announced a grant to spatially map cortical cells using Fluorescent in situ Sequencing (FISSEQ) for the Human Cell Atlas.

The grant is from the Chan Zuckerberg Initiative (CZI) and DAF, an advised fund of Silicon Valley Community Foundation.

Human breast tissue, Credit: Wyss Institute

The collaboration’s goal is to benchmark in situ technologies and establish best practices for the Human Cell Atlas. The atlas will contain in depth variance maps of cell transcriptomes, genomes, proteomes, metabolomes, and epigenetic landscapes.

FISSEQ will provide deep insight into cell variation in the context of the tissue microenvironment, a feature that is difficult or impossible to obtain with traditional in situ methods.

Human fibroblasts, Credit: ReadCoor

FISSEQ also uniquely delivers researchers an opportunity to locate genes that have mutated away from the original sequence due to its ability to produce reads without known gene targets. Most standard in situ methods are blind to such changes and can miss altered genes.

Mouse Lung Tissue, Credit: ReadCoor

The research project is part of an Allen Institute-led consortium of world-class research institutions. Members include the Allen Institute for Brain Science, Broad Institute, California Institute of Technology, Cold Spring Harbor Laboratory, Harvard University, Karolinska Institute, KTH Royal Institute of Technology, Massachusetts Institute of Technology, Stockholm University, and the University of California, San Diego.

Human fibroblasts, Credit: ReadCoor

Credit: Bella Wang Photography

“Our team is honored to be part of this consortium of world-leading academic scientists to contribute to the Human Cell Atlas. We look forward to working with our fellow collaborators to deliver a robust map of cortical cells and transcend our foundational understanding of health and disease.”

—Shawn Marcell
Co-founder, Chairman & CEO

About Fluorescent in situ Sequencing (FISSEQ)

FISSEQ is a spatial sequencing technology that reads and visualizes the three-dimensional coordinates of molecules of intact tissue, a capability that stands to revolutionize panomics and pathology.

FISSEQ was developed in the Church Lab at Harvard University and the Wyss Institute for Biologically Inspired Engineering, and first published in Science in 2014 ( Highly multiplexed three-dimensional subcellular transcriptome sequencing in situ ).

The platform has broad application in the areas of drug development, diagnostics, and machine learning.

About ReadCoor, Inc.

ReadCoor is leading the next generation of omics by delivering the first panomic spatial sequencing platform to the global audience of researchers, clinicians, pharma and diagnostics companies, and ultimately patients. It is accomplishing this with Fluorescent in situ Sequencing (FISSEQ), a fundamental new technology, which simultaneously integrates high-throughput sequencing, and three-dimensional morphometric analysis. This uniquely powerful platform is expected to revolutionize the next phase in understanding the panomic landscape and introduce vast new opportunities for important and meaningful clinical insight.

Contact


Start Over